Cardiff Oncology to Present Onvansertib Phase 2 Data at ASCO 2026

Cardiff Oncology has announced plans to present updated interim data from its Phase 2 CRDF-004 trial at the prestigious ASCO 2026 Annual Meeting in Chicago on June 2, 2026. The presentation will showcase results evaluating onvansertib, a PLK1 inhibitor (polo-like kinase 1 inhibitor), in combination with standard chemotherapy and bevacizumab for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC). The rapid oral session format underscores the clinical significance of the data and positions the company's lead asset as a potentially transformative treatment option for this difficult-to-treat patient population.

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, and patients with RAS-mutated tumors face particularly poor prognosis due to limited targeted treatment options. The presentation of updated interim data at a major oncology conference signals progress in Cardiff Oncology's clinical development pipeline and reflects growing momentum in the company's pursuit of regulatory approval for onvansertib in this indication.

Phase 2 Trial Details and Clinical Significance

The CRDF-004 trial represents a critical milestone in evaluating onvansertib's potential to address an unmet medical need in first-line mCRC treatment. Key aspects of the trial design include:

• Patient population: First-line RAS-mutated metastatic colorectal cancer patients
• Treatment regimen: Onvansertib combined with standard chemotherapy and bevacizumab
• Mechanism of action: PLK1 inhibition—targeting polo-like kinase 1, a regulator of cell division and mitotic progression
• Presentation format: Rapid oral session at ASCO 2026, indicating data of significant clinical interest
• Update timing: Interim data presentation, suggesting ongoing trial recruitment and maturation

The rationale for combining onvansertib with established chemotherapy agents reflects a rational drug development approach aimed at enhancing treatment efficacy. RAS mutations, which occur in approximately 40-50% of colorectal cancers, have historically been considered "undruggable," forcing oncologists to rely on conventional cytotoxic chemotherapy regimens. By pairing onvansertib with standard-of-care treatments, Cardiff Oncology is pursuing a strategy that could potentially improve outcomes without requiring patients to abandon proven therapeutic approaches.

Market Context and Competitive Landscape

The colorectal cancer treatment market has witnessed significant evolution in recent years, with several targeted therapies gaining approval for specific patient subsets. However, RAS-mutated mCRC remains an area with substantial unmet medical need. Current treatment landscape considerations include:

• Standard-of-care baseline: Chemotherapy-based regimens (FOLFOX, FOLFIRI) remain foundational for first-line treatment
• Bevacizumab integration: Anti-VEGF therapy combined with chemotherapy represents current standard practice
• Emerging competition: Various companies are developing novel approaches to target RAS mutations and related pathways
• Market opportunity: Significant patient population globally requiring effective first-line treatment options
• Regulatory environment: FDA maintains focus on advancing treatments addressing unmet oncology needs

The timing of this ASCO 2026 presentation comes as the oncology field increasingly recognizes the limitations of current RAS-mutated cancer management. While recent advances have emerged in addressing KRAS mutations specifically through inhibitors like sotorasib (sold as Lumakras) and adagrasib (Krazysana), these agents primarily benefit specific KRAS G12C mutations. The broader RAS-mutated population, including different mutation subtypes, still lacks dedicated targeted options, creating a substantial opportunity for combination approaches like onvansertib.

Investor Implications and Clinical Development Path

For shareholders and market observers, the ASCO 2026 presentation carries several important implications:

Near-term catalysts: The data presentation represents a key value inflection point for Cardiff Oncology, with the potential to influence clinical perception and investor sentiment regarding onvansertib's commercial viability.

Regulatory trajectory: Positive interim data could strengthen Cardiff Oncology's case for advancing to late-stage development or potentially support accelerated regulatory pathways, depending on efficacy and safety profiles demonstrated.

Competitive positioning: Strong Phase 2 results would position onvansertib as a meaningful addition to the RAS-mutated mCRC treatment armamentarium, potentially capturing significant market share if approved.

Commercial potential: First-line colorectal cancer treatment represents a substantial revenue opportunity given the patient population size and treatment duration required, making this indication commercially attractive.

Clinical validation: Presentation at ASCO—one of the world's most prestigious oncology conferences—provides significant credibility and visibility among practicing oncologists, potentially influencing adoption patterns upon regulatory approval.

Investors should monitor the specific efficacy metrics (overall survival, progression-free survival, response rates) and safety data presented, as these will directly influence the likelihood of regulatory approval and ultimate market success. The strength of the interim data could also determine whether Cardiff Oncology pursues accelerated development programs or requires additional trial expansion.

Looking Forward

The ASCO 2026 Annual Meeting presentation marks a pivotal moment for Cardiff Oncology and its efforts to advance onvansertib into clinical practice. As the company prepares to showcase updated Phase 2 CRDF-004 data, the oncology investment community will scrutinize safety profiles, efficacy endpoints, and patient benefit assessment relative to current standard-of-care approaches. The combination of PLK1 inhibition with chemotherapy and bevacizumab represents a rational therapeutic strategy for RAS-mutated mCRC, an area where treatment options have historically been limited. Should the interim data demonstrate clinically meaningful improvements over existing approaches, Cardiff Oncology could establish onvansertib as a transformative treatment option for thousands of patients annually, while creating significant shareholder value. Market participants should prepare for potential volatility surrounding the June 2026 presentation and maintain awareness of ongoing trial enrollment and secondary clinical developments from Cardiff Oncology's pipeline.